Download these slides from an expert-led symposium reviewing updates in oral targeted therapy for HR-positive/HER2-negative breast cancer and implementation in clinical practice.
In this commentary, we discuss updates on the use of oral targeted therapies for the treatment of HR-positive/HER2-negative early and metastatic breast cancer, adverse event management, and tools for adherence.
Listen to the experts discuss current and emerging oral targeted therapies for advanced HR+/HER2- breast cancer, adverse event management, and strategies to promote adherence.
Contact Clinical Care Options
For customer support please email: customersupport@cealliance.com
Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.